SCHEMBL13154685

SCHEMBL13154685

c1ccc2cc3cc4c(cc3cc2c1)CCN4

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.53
MEN1 O00255 3/20 0.53
KMT2A Q03164 3/20 0.53
ALOX15 P16050 2/20 0.53
CASP1 P29466 2/20 0.53
CASP7 P55210 2/20 0.53
HSD17B10 Q99714 2/20 0.53
HPGD P15428 2/20 0.53
LMNA P02545 1/20 0.53
TP53 P04637 1/20 0.53
POLB P06746 1/20 0.53
GAA P10253 1/20 0.53
ALOX12 P18054 1/20 0.53
MPI P34949 1/20 0.53
HTT P42858 1/20 0.53
DRD2 P14416 1/20 0.46
DRD4 P21917 1/20 0.46
MAPT P10636 2/20 0.38
PARP10 Q53GL7 2/20 0.37
PARP11 Q9NR21 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5755884 0.96 ALDH1A1 (0.56) ALDH1A1MEN1KMT2AALOX15CASP1
SCHEMBL1437934 0.84 ALDH1A1 (0.49) ALDH1A1MEN1KMT2AALOX15CASP1
SCHEMBL19198509 0.81 MEN1 (0.52) ALDH1A1MEN1KMT2AALOX15CASP1
SCHEMBL13154637 0.76 CHRNB2 (0.43) ALDH1A1MEN1KMT2AALOX15CASP1
SCHEMBL13154655 0.76 CHRNB2 (0.43) ALDH1A1MEN1KMT2AALOX15CASP1
SCHEMBL19198939 0.75 MEN1 (0.55) ALDH1A1MEN1KMT2AALOX15CASP1
SCHEMBL4496862 0.75 DRD2 (0.56) ALDH1A1DRD2DRD4MAPTPARP10
SCHEMBL13154647 0.74 NPC1 (0.43) ALDH1A1MEN1KMT2AALOX15CASP1
SCHEMBL7469992 0.74 DRD2 (0.41) ALDH1A1MEN1KMT2AALOX15CASP1
SCHEMBL13154657 0.74 POLB (0.43) ALDH1A1MEN1KMT2AALOX15CASP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11980086-B2 Use of transition metal carbene complexes in organic light-emitting diodes (OLEDs) UDC IRELAND LIMITED (IE) 2024-05-07 US disclosed
US-20240074302-A1 USE OF TRANSITION METAL CARBENE COMPLEXES IN ORGANIC LIGHT-EMITTING DIODES (OLEDS) UDC IRELAND LTD (IE) 2024-02-29 US disclosed
US-20140309428-A1 USE OF TRANSITION METAL CARBENE COMPLEXES IN ORGANIC LIGHT-EMITTING DIODES (OLEDS) BASF SE (DE) 2014-10-16 US disclosed
US-7803948-B2 Method for the isomerisation of transition metal complexes containing cyclometallated, carbene ligands BASF AKTIENGESELLSCHAFT (DE) 2010-09-28 US disclosed
US-20080200686-A1 Method for the Isomerisation of Transition Metal Complexes Containing Cyclometallated, Carbene Ligands BASF AKTIENGESELLSCHAFT (DE) 2008-08-21 US disclosed
US-20080018221-A1 Use Of Transition Metal Carbene Complexes In Organic Light-Emitting Diodes (Oleds) BASF AKTIENGESELLSCHAFT (DE) 2008-01-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080200686-A1 Method for the Isomerisation of Transition Metal Complexes Containing Cyclometallated, Carbene Ligands SCO2, CYC1, CHRM1 ALDH1A1 2599/4885MEN1 1908/4885KMT2A 3632/4885
US-11980086-B2 Use of transition metal carbene complexes in organic light-emitting diodes (OLEDs) OCIAD2, OCIAD1, ICOSLG ALDH1A1 1981/4885MEN1 3106/4885KMT2A 3552/4885
US-20080018221-A1 Use Of Transition Metal Carbene Complexes In Organic Light-Emitting Diodes (Oleds) OCIAD2, OCIAD1, ICOSLG ALDH1A1 1981/4885MEN1 3106/4885KMT2A 3552/4885
US-20240074302-A1 USE OF TRANSITION METAL CARBENE COMPLEXES IN ORGANIC LIGHT-EMITTING DIODES (OLEDS) OCIAD2, OCIAD1, ICOSLG ALDH1A1 1981/4885MEN1 3106/4885KMT2A 3552/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.